Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMINO ACIDS vs AMINOSYN 3.5%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.
Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.
Total parenteral nutrition (TPN) for patients unable to ingest or absorb adequate nutrients,Supplementation in metabolic disorders (e.g., urea cycle disorders, maple syrup urine disease),Treatment of negative nitrogen balance due to trauma, burns, or surgery
Parenteral nutrition for prevention of nitrogen loss or treatment of negative nitrogen balance in patients where oral/enteral nutrition is impossible or insufficient
1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.
Intravenous administration of 500 m L to 1000 m L per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 m L/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.
Variable; endogenous amino acids: 10–30 min for clearance from plasma; administered doses: distribution half-life ~5–10 min, terminal elimination half-life ~15–30 min, reflecting rapid metabolic utilization and renal reabsorption.
The plasma half-life of individual amino acids varies; for total amino acid mixture, the terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic and renal function, reflecting rapid uptake into tissues and metabolism. This half-life is clinically relevant for continuous infusion scheduling.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Specific pathways exist for each amino acid; excess nitrogen is converted to urea.
Amino acids are metabolized primarily in the liver via deamination, transamination, and urea cycle; some metabolism occurs in peripheral tissues.
Renal: >95% as amino acids and metabolites, primarily reabsorbed; <5% unchanged. Fecal/biliary: negligible (<1%).
Amino acids are primarily eliminated via hepatic metabolism (deamination, transamination) and renal excretion. The renal excretion accounts for approximately 5-10% of the administered dose as unchanged amino acids; the majority is metabolized, and nitrogen is excreted as urea (80-90% of nitrogen) via urine, with minor fecal losses (<5%).
Minimal for most amino acids (<10%); albumin and globulins bind tryptophan and aromatic amino acids (~80–90% for tryptophan).
Amino acids have minimal protein binding (less than 10%), primarily to albumin, but binding is negligible for pharmacokinetic purposes.
0.4–0.6 L/kg (total body water); reflects equilibration with intracellular and extracellular fluid compartments.
Volume of distribution for amino acids is approximately 0.2-0.4 L/kg, reflecting distribution primarily into extracellular fluid and lean tissue compartments. This low Vd indicates limited extravascular distribution.
Oral: ~90–100% (active transport across intestinal mucosa); IV: 100%.
Intravenous: 100% bioavailability. Not applicable to other routes; oral administration is not indicated due to first-pass metabolism and variable absorption.
For GFR <30 m L/min: reduce dose to 0.5-1 g/kg/day; monitor serum amino acids and nitrogen balance.
For GFR 30-59 m L/min: reduce dose by 50% and monitor serum BUN. For GFR 15-29 m L/min: reduce dose by 75%. For GFR <15 m L/min: avoid use unless on renal replacement therapy; if used, adjust based on amino acid losses during dialysis.
Child-Pugh B or C: avoid standard formulations; use branched-chain amino acid (BCAA)-enriched solutions at 0.8-1.2 g/kg/day.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and monitor ammonia levels. Child-Pugh Class C: avoid use or use with caution, reduce dose by 75% and monitor for hepatic encephalopathy.
0.5-2 g/kg/day IV; titrate based on age, growth, and metabolic needs.
Intravenous infusion of 1-2 g amino acids/kg/day (equivalent to 28.6-57.1 m L/kg/day of 3.5% solution). For preterm infants: start at 1 g/kg/day and advance by 0.5 g/kg/day to target 2-3 g/kg/day. Titrate based on serum amino acid profiles and growth parameters.
Initiate at 0.8 g/kg/day IV, adjust based on renal function and nitrogen balance; monitor for fluid overload.
No specific dose adjustment based on age alone; however, elderly patients often have reduced renal function and lean body mass. Initiate at lower end of dosing range (e.g., 0.5 g amino acids/kg/day) and titrate slowly, monitoring renal function and fluid status.
Patients receiving amino acid infusions should be monitored for metabolic acidosis, hyperammonemia, and renal function impairment. Solutions with electrolytes should not be used in patients with severe electrolyte imbalances.
None
Use with caution in patients with renal impairment, hepatic failure, heart failure, or metabolic acidosis. Monitor serum electrolytes, blood urea nitrogen, and ammonia levels. Avoid rapid infusion to prevent hyperosmolarity and venous thrombosis.
Risk of metabolic acidosis,Hepatic and renal impairment may require dose adjustment,Monitor serum electrolytes, fluid balance, and ammonia levels,Do not administer if solution is cloudy or contains particulates
Hypersensitivity to any component, inborn errors of amino acid metabolism (e.g., phenylketonuria) without specific formula, severe hyperammonemia, anuria, or metabolic acidosis.
Hypersensitivity to any component,Inborn errors of amino acid metabolism,Severe hepatic failure or hepatic coma,Severe azotemia or uremia not related to dialysis
No significant food interactions; however, enteral nutrition should be managed to avoid excessive protein intake. Patients with phenylketonuria must avoid phenylalanine-containing amino acid solutions.
No direct food interactions, as this is administered intravenously. However, concurrent oral intake should be avoided until parenteral nutrition is adjusted. Monitor for refeeding syndrome if transitioning to oral nutrition.
Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimester-specific human data; animal studies show no teratogenicity at standard doses.
Aminosyn 3.5% is an amino acid solution used for parenteral nutrition. No specific teratogenic risk has been established in human pregnancy; however, maternal malnutrition may pose risks. During pregnancy, use only if clearly needed due to the risk of electrolyte imbalances, fluid overload, or metabolic disturbances that could affect the fetus. There are no adequate studies in pregnant women. The potential for fetal harm based on animal reproduction studies is not available.
Amino acids are normal constituents of breast milk; supplementation likely results in increased maternal levels but endogenous secretion maintains relatively constant milk levels. M/P ratio not established; generally considered compatible with breastfeeding at recommended doses.
It is not known whether amino acids from Aminosyn 3.5% are excreted in human breast milk. The M/P ratio is not established. Caution should be exercised when administered to a nursing woman, as the effect on the breastfed infant is unknown. Consider the benefits of breastfeeding and the mother's need for the drug.
No specific dose adjustments required for enteral amino acids. For parenteral nutrition, consider increased requirements in third trimester (protein needs up to 1.5 g/kg/day). Adjust based on maternal weight gain, renal function, and metabolic monitoring.
Dosing adjustments may be necessary due to increased plasma volume and altered protein metabolism in pregnancy. Increased requirements for certain amino acids (e.g., threonine, lysine) may need to be considered. Monitor nitrogen balance and adjust total amino acid dose based on maternal weight, gestational age, and clinical response. Close monitoring of plasma amino acid levels and metabolic parameters is recommended to avoid excess or deficiency.
Amino acid infusions should be administered via central line if osmolarity > 900 m Osm/L to prevent thrombophlebitis. Monitor serum ammonia and BUN in patients with hepatic or renal impairment. Use with caution in patients with inborn errors of amino acid metabolism.
AMINOSYN 3.5% is a crystalline amino acid solution used for parenteral nutrition. Monitor serum electrolytes, blood urea nitrogen (BUN), and ammonia levels. Do not administer simultaneously with blood products via same infusion line due to risk of incompatibility. Use with caution in patients with hepatic or renal impairment. Central line administration is required for concentrations >5%, but 3.5% can be infused via peripheral vein if adequately diluted and with careful monitoring for thrombophlebitis.
This medication provides essential building blocks for protein synthesis.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your doctor if you have liver or kidney disease.,Do not take other protein supplements unless directed by your healthcare provider.
This medication is given intravenously to provide protein when you cannot eat normally.,You may require regular blood tests to monitor kidney and liver function, as well as electrolyte levels.,Report any signs of infection at the IV site, such as redness, swelling, or warmth.,Do not stop or adjust the infusion rate without your healthcare provider's guidance.,Inform your doctor if you have diabetes, liver disease, or kidney disease.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMINO ACIDS vs AMINOSYN 3.5%, answered by our medical review team.
AMINO ACIDS is a Parenteral Nutrition Solution that works by Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.. AMINOSYN 3.5% is a Parenteral Nutrition Solution that works by Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMINO ACIDS and AMINOSYN 3.5% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMINO ACIDS is: 1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.. The standard adult dose of AMINOSYN 3.5% is: Intravenous administration of 500 m L to 1000 m L per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 m L/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMINO ACIDS and AMINOSYN 3.5% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMINO ACIDS is classified as Category C. Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimest. AMINOSYN 3.5% is classified as Category C. Aminosyn 3.5% is an amino acid solution used for parenteral nutrition. No specific teratogenic risk has been established in human pregnancy; however, maternal malnutrition may pose. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.